Biotech | April 13, 2022
Switzerland grants conditional marketing authorisation for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
New line of Waters MaxPeak Premier columns further enhances the analysis by delivering 2x to 3x greater sensitivity than conventional steel columns
Sputnik Light is the first component of Sputnik V
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
Subscribe To Our Newsletter & Stay Updated
